French regulator agrees to partial resumption of Tellomak trial patient recruitment

14 Jan 2020

The French National Agency for Medicines and Health Product Safety (ANSM) has agreed that Innate Pharma’s Tellomak (lacutamab) Phase II trial can resume recruitment of new patients with relapsed/refractory Sézary syndrome and mycosis fungoides (MF) in France, the biotech firm said late Monday.

Lacutamab is an anti-KIR3DL2 antibody being developed for the treatment of the rare cancer cutaneous T-cell lymphoma.

French regulator agrees to partial resumption of Tellomak trial patient recruitment

“The ANSM decision to allow new patient recruitment to resume in Sézary syndrome and MF in France is based on an assessment of the unmet medical need and the lack of currently available standard of care options,” Innate Pharma said.

Innate said it would take operational measures to reactivate the Tellomak trial for Sézary and MF patients in France and the UK where regulators have authorized it.

However, due to wider available treatment options, no new T-cell lymphoma patients can enrol in the trial until a new Good Manufacturing Practice (GMP)-certified batch is available.

The Tellomak trial has been on partial clinical hold since December 13 in France and the UK and since January 9 in the US. Innate has been in ongoing discussions with US and European regulators over GMP deficiencies at its manufacturing subcontractor’s site that manages fill and finish operations for Tellomak.

Despite being awarded GMP certification by the Austrian Agency for Health and Food Safety in August 2018, Rentschler Fill Solutions (RFS) unilaterally withdrew the Certificate of Conformity guaranteeing the quality of batches produced at the plant in November last year.

RFS has also filed for bankruptcy, according to Innate.

Related news

Pioneer in Phenylketonuria to begin clinical trial with gene therapy

Pioneer in Phenylketonuria to begin clinical trial with gene therapy

15 Jan 2020

BMN 307 represents a potential third PKU treatment option from BioMarin and its second gene therapy clinical program.

Read more 
Biogen to acquire novel clinical-stage asset from Pfizer

Biogen to acquire novel clinical-stage asset from Pfizer

14 Jan 2020

PF-05251749 complements the company’s pipeline of potential disease-modifying therapies for Alzheimer’s and Parkinson’s diseases.

Read more 
Partnership formed to develop and commercialise ready-to-use medicine

Partnership formed to develop and commercialise ready-to-use medicine

13 Jan 2020

The product being developed will use proprietary drug formulation technology platform Arestat to deliver new reformulations of existing, complex products.

Read more 
ReadCoor to commercially launch spatial sequencing platform

ReadCoor to commercially launch spatial sequencing platform

10 Jan 2020

Platform gives researchers access to previously undiscovered data to guide evaluation and validation of new drug targets, pathogen identification, disease diagnosis, and the advancement of regenerative medicine.

Read more 
New HQ for developer of world's first fully automated drug discovery platform

New HQ for developer of world's first fully automated drug discovery platform

8 Jan 2020

End-to-end robotic platform provides biotechnology companies, pharmaceutical corporations and academic centres with cost-effective and reproducible drug discovery data.

Read more 
NIH researchers discover new autoinflammatory disease

NIH researchers discover new autoinflammatory disease

3 Jan 2020

Mutations in the RIPK1 gene responsible for CRIA syndrome.

Read more 
BioAscent scientists help identify potential new treatments for cancer

BioAscent scientists help identify potential new treatments for cancer

30 Dec 2019

Collaboration discovers potent and selective inhibitors of enzymes associated with the development of some cancers and neurodegenerative diseases.

Read more 
NIH launches first US clinical trial of patient-derived stem cell therapy to replace dying cells in retina

NIH launches first US clinical trial of patient-derived stem cell therapy to replace dying cells in retina

13 Dec 2019

NEI-led study to test safety of treatment for a form of age-related macular degeneration that currently lacks treatment.

Read more 
Sanofi bolsters its immuno-oncology pipeline for $2.5B

Sanofi bolsters its immuno-oncology pipeline for $2.5B

6 Dec 2019

Lead asset THOR-707 being explored across multiple solid tumor types alone and in combination with immune checkpoint inhibitors and other future IO combinations.

Read more 
Catalent to partner with Ethicann on new fast-dissolve cannabinoid-based treatment

Catalent to partner with Ethicann on new fast-dissolve cannabinoid-based treatment

4 Dec 2019

Program will initially focus on using Catalent’s orally disintegrating tablet technology to develop a combination pharmaceutical-grade CBD and THC product that, if approved, would treat patients suffering from MS spasticity.

Read more